Replies to post #727980 on NorthWest Biotherapeutics Inc (NWBO)

[Reefrad]

I somewhat disagree. Most newly diagnosed GBM patients are rushed off to surgery and never have the chance to research DCVAX before the turn is taken out and it's too late to use the tissue. Also most doctors will not recommend and experimental treatment that has not yet received some sort of regulatory approval.

[dennisdave]

It's not a new narrative, it's an existing narrative that has already been proven true.

DCVax-L has been available as a treatment, commercially, in the UK for over a year now.

Why aren't GBM patients flooding in from all around the globe to receive treatment?

I will answer that. The reason is that a medical doctor in lets say Switzerland or Norway will pay so much more attention to a cancer drug that can save a life and is regulated in the UK than a medical drug that is simply not regulated with an RA with repute such as the FDA, MHRA or EMA. Any MD will tell you that as such is a world of difference. So yeah after UK approval patients who can afford DCVAXL all over the globe will be directed to the UK by their MD.

[DrHigh]

Everytime I hear a number quoted of patients treated it is higher than a previous one. So it appears we are treating some patients but the revenue generated is showing up somewhere else? Advent? Toucan? I have no idea

[NotSure2]

FEMike, you are so wrong, look at DStock post (hundreds if not thousands) about Merck recruiting more staff this past Dec-Jan-Feb. Flooding NWBO msg boards with up to 10 recruitment post per day.

Has to be directly related to Merck acquring NWBO, and making DCVAX in advance. Once approved, you ll get BILLIONS of vaccine, and NWBO will be worth TRILLIONS!!! With NICE reimbursment right away as well!! Next week, next week!!

😅🤣😂🤣😂

[KRISGO]

FeMike, to my knowledge, most patients or their families don’t make decisions independently, they may seek a second opinion to verify what their doctor has identified. Generally, they tend to follow their doctor’s advice instead of relying solely on their own research, mainly because of fear. If they stray from their doctor’s recommendations, they might hesitate to return to that same doctor. Many in the older generation distrust information from Google and believe that doctors provide more reliable guidance. Even when patients bring up their online research, doctors may suggest different treatment options, which ultimately places the decision-making in their hands. As a result, most patients and their families prefer to trust their doctors’ recommendations, and it’s usually the doctor who determines the appropriate treatment plan. If DCVAX-L is approved by the MHRA and becomes public news, it will likely gain significant attention, and most doctors will make decisions based on approved treatments.

DCVax-L has been available as a treatment, commercially, in the UK for over a year now.

Why aren't GBM patients flooding in from all around the globe to receive treatment? Why isn't NWBO reporting sold out manufacturing revenue? You think just because it isn't approved, potential patients don't know about it?

If you get diagnosed with GBM, the first thing you are doing is googling for trials and treatment options. The average Joe doesn't have a clue what DCVax is, but it isn't hard to find if you're looking for it with purpose.

[biosectinvestor]

It can't be marketed, it doesn't make doctors wealthy like the helmet, it is only compassionate use and requires a large out of pocket, up front investment. So that narrative that it is already available and there is no market for it... is premature and not an accurate read for an approved drug, that can be marketed and where, and this is important, word has gotten out, because it still won't be possible to market it in other countries. 

Approval will be a major game changer because it means it is likely approvable in these other markets however, and that should open up more opportunities for company collaboration with other potential partners, probably accelerate discussions on deals and make things a lot easier at least when they have a reasonable revenue stream. The UK is closer to Europe, but you don't see a lot of medical tourism to the UK historically. But could happen. Just not a common thing. 

I do expect, if the UK approved and given previous German favorability, you could see an approval from the EMA as highly likely. I also think it will be highly influential on the FDA to accelerate their efforts to get this to market in the U.S.